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Lacosamide (LCM) is an antiepileptic drug (AED) that was introduced into the European market in 2008. LCM was originally licensed as an add-on AED for adults, aged 16 years and older, with focal epilepsy either with or without secondary generalized seizures. In 2014, LCM was authorized as a monotherapy for the treatment of focal epilepsy by the U.S. Food and Drug Administration (FDA), and in 2016 by the European Medicines Agency (EMA). The half-life of LCM is 13 h for young adults, and the drug has no known pharmacokinetic interactions with other AEDs. In contrast to traditional sodium channel blockers (SCBs), which act through the fast inactivation of voltagegated sodium channels (VGSCs), LCM acts through the slow inactivation of VGSCs. According to Cawello 1, 2 "this [sodium channel activation] mechanism of action results in stabilization of hyperexcitable neuronal membranes, inhibition of neuronal firing and reduction in long-term channel availability without affecting physiological function." Following the licensure of LCM, several clinical trials, which included mostly adult patients without intellectual disabilities (IDs), were conducted to evaluate the efficacy and safety of the drug. [3] [4] [5] According to a pooled analysis of phase II/III studies, LCM provides additional efficacy when combined with a broad range of AEDs 6 and is generally well tolerated. 3, 7 Adverse events are mostly dose dependent; restricted to the central nervous system and gastrointestinal system; and include dizziness, diplopia, somnolence, headache, nausea, and/or vomiting. 6 Other trials have demonstrated a significant decrease in LCM efficacy in the presence of other SCBs. 8, 9 In general, there is a lack of evidence-based information available on the efficacy and tolerability of AEDs in patients with IDs and epilepsy. Around one fourth of patients with epilepsy have an ID (defined as an Intelligence Quotient [IQ] <70). 10 Thus, in contrast to the above-mentioned trials, the focus of this study was on the tolerability and efficacy of LCM in adult patients with epilepsy and IDs. In this subgroup of patients, adverse events (AEs) are hard to recognize, 11 since individuals are often unable to articulate the side effects or efficacy of AED treatment. Therefore, we used retention rate as an indirect measure of the effectiveness of LCM. Moreover, because McGinnis et al. 9 revealed that concomitant SCB use is a key factor for increased risk of LCM failure in children, a second focus of this study was on the tolerability of LCM with concomitant SCB treatment.
Methods

Study design and patient population
We conducted a monocentric, retrospective, observational, open-label study to evaluate LCM retention rates in a sample of patients with epilepsy 12 and IDs. In the second part of the analyses, factors influencing retention rate and the impact of concomitant SCB use on LCM long-term retention rate were evaluated. Our retrospective chart review qualified for a waiver of consent, which was approved by the Federal Ethics Review Board.
Patients were included if they presented drug-resistant epilepsy, according to Kwan et al., 13 if they had an ID, according to the International Classification of Diseases (ICD 10), and if they had never taken LCM before. In most cases, the degree of ID was determined through referral letters or previous clinical reports. If this information was incomplete or contradictory, in-depth clinical assessment or, in some instances, standardized intelligence testing, was conducted. Patients with nonepileptic seizures were excluded. Treatment with LCM was initiated for all patients between 2008 and 2015 in our outpatient and inpatient clinics; the criterion for LCM initiation was failure of previous treatments. LCM drug dosage and concomitant medication dosages were set in accordance with the treating physician's usual clinical practice. According to individual patient need, dosages were taken twice a day and ranged between 100 and 800 mg/day. LCM was administered in three single doses to patients who experienced AEs, according to Sattler et al. 14 Concomitant AEDs were designated as SCB according to McGinnis et al. 9 and included oxcarbazepine (OXC), carbamazepine (CBZ), phenytoin (PHT), and lamotrigine (LTG). Follow-up examinations were conducted mostly in our outpatient clinic, with the minimum follow-up period being 4 weeks. Reasons for discontinuation were based on notations in the clinical records.
Statistical analysis
A Kaplan-Meier analysis 15 was conducted to evaluate the LCM retention rate in general. Log-rank tests were run to evaluate factors influencing retention rate and to compare the LCM retention rate in patients taking concomitant SCB to those who were not. Chi-square and Mann-Whitney U tests were used to compare the equivalence of the independent groups. All statistical analyses were performed using the software package SPSS 15 (SPSS Inc, Chicago, IL, U.S.A.).
Results
Patients
We included 136 patients (62 women, 46%; age 2-66 years). Nearly all patients had mild-to-profound IDs (F70 to F73, according to the ICD-10). In 43 patients (31.6%), IDs were associated with significant behavior impairments, reflecting the complex relationship among IDs, epilepsy, and behavioral disorders as stated in Kerr et al. 16 Most patients had focal epilepsy 17 (96%) and were drug resistant. Moreover, 86.8% of the patients were taking one or two AEDs at the time of LCM treatment initiation.
The mean LCM dosage was 411.0 mg (standard deviation [SD] 119.1 mg), and the target dosage was titrated after evaluating seizure frequencies and AEs. The most commonly selected LCM dosage was 400 mg/day (in 61 of 136 patients). In about one third of the patients, LCM was initiated as add-on polytherapy, whereas in two thirds of the patients, another AED was withdrawn and LCM was initiated. Baseline demographic data and clinical characteristics are shown in Table 1 .
In the current study, we compared the following two groups of patients: those receiving concomitant SCB agents (PHT, CBZ, OXC, and/or LTG) and those receiving LCM without concomitant SCB agents. At the time LCM was initiated, 61 patients (44.9%) were taking one or more
Key points
• About 60% of patients with epilepsy and IDs retained LCM treatment after 1 year, whereas about 30% continued use after 3 years
• The LCM retention rate was influenced by the number of background AEDs
• Combined use of LCM with SCB had no additional or independent negative impact on LCM long-term retention concomitant SCBs. More specifically, 37 patients were taking LTG, 16 were taking OXC, 7 were taking CBZ, and 3 were taking PHT. Moreover, 2 of the 61 patients were taking two SCBs at the time LCM was initiated. In patients receiving concomitant SCBs, the total number of concurrent AEDs at LCM start was higher (Mann-Whitney U test, U = 1259, z = À4.926, p < 0.001). Furthermore, the proportion of patients in which LCM was initiated as add-on polytherapy was higher in the SCB group (v 2 (1) = 10.561, p = 0.001). There were no further significant differences in demographic data and clinical characteristics between the groups (Table 1) .
A Kaplan-Meier analysis 15 was conducted to estimate LCM retention rates in the total sample of 136 patients. Long-term retention rates on LCM therapy were 62.0% at 1 year, 43.7% at 2 years, and 29.1% at 3 and 4 years ( Table 2 , Fig. 1 ). After 1.5 years (95% confidence interval [CI] 1.1-1.9), 50% of the patients were still being treated with LCM (median retention).
The most common reasons for discontinuation in noncensored patients were insufficient therapeutic benefit (69%), AEs (e.g., dizziness, fatigue, diplopia, and/or vomiting; 11%), or a combination of both (8%). In the remaining 11% of patients, rationale for stopping LCM use remains unknown. Five patients were included in an off-label condition. Three patients with Dravet syndrome received LCM for 32, 48, and 96 weeks; the remaining two patients with symptomatic generalized epilepsy were treated with LCM for 8 and 44 weeks.
Next, we aimed to investigate the impact of therapyrelated factors on retention rates using Kaplan-Meier analyses with log-rank tests. To achieve this, we first analyzed retention rates in patients receiving different daily doses of LCM. This point was of special interest because patients with IDs were prescribed a mean daily dose of LCM that was higher than the maximum FDA approved dose in the United States (411 mg vs. 400 mg). Because 400 mg is the most frequently prescribed dose of LCM, we separated patients into the following three groups: <400 mg (n = 34), 400 mg (n = 61), and >400 (n = 41). The respective log-rank test was not significant (v 2 (2) = 2.485, p = 0.289) therefore, an effect of LCM dose on retention rates could not be proved in our sample. We then asked if retention rates differed in patients in which LCM was initiated as an add-on therapy (n = 51) versus patients in whom LCM substituted for another AED (n = 85); a log-rank test revealed no significantly different distributions between the two treatment groups (v 2 (1) = 0.147, p = 0.701). To investigate the impact of the number of background AEDs on retention rate, we divided the total sample into a group where patients had zero or one background AED (n = 66) and a group where patients had two to four background AEDs (n = 70). The respective log-rank test revealed significantly different distributions between these two groups (v 2 (1) = 5.662, p = 0.017). The number of concurrent AEDs had a significant negative impact on retention rate. Finally, we compared LCM retention rates in patients taking concomitant SCBs (n = 61) to those who were not (n = 75). Descriptive statistics revealed that patients taking LCM and concomitant SCB agents exhibited a higher number of concurrent AEDs at LCM start and more frequently got LCM as an add-on therapy (see Table 1 ). Because only the number of concurrent AEDs had a significant impact on retention rate, we introduced this as a control variable. A KaplanMeier analysis with concomitant SCB (yes/no) as a factor and number of background AEDs (zero to one vs. two to four) as strata was then performed. The log-rank test revealed no significantly different distributions between the patients with or without concomitant SCBs, neither in stratum 1 (zero to one background AED; v 2 (1) = 0.028, p = 0.868), nor in stratum 2 (two to four background AEDs; v 2 (1) = 1.657, p = 0.198). Moreover, the overall comparison pooled over strata 1 and 2 was also not significant (v 2 (1) = 1.371, p = 0.242).
Discussion
The prevalence of epilepsy in individuals with IDs is higher than in the general population and is also more difficult to treat. 18 One of the major challenges in managing patients with epilepsy and IDs is the high rate of drug resistance in this population. For example, in a population-based prevalence study, McGrother et al. 18 found that 68% of adults with IDs and epilepsy experience seizures despite adequate AED treatment. Thus the development of AEDs is extremely welcome to provide these patients with new treatment options. However, there is a lack of evidence-based information available about the efficacy and tolerability of AEDs in patients with IDs with epilepsy. Moreover, it is difficult to determine if the application of new drugs will be worthwhile. To address these issues, the present observational trial examined LCM retention rates among patients with drug-resistant epilepsy and ID. We chose retention rate as a combined measure of tolerability and efficacy, since more direct assessments are hard to achieve in patients with IDs. 11 Due to communication barriers, most patients with profound IDs were unable to answer whether they were experiencing any adverse events; thus negative side effects were assessed by observations of behavior changes or by reports from caregivers.
Our study has shown that long-term retention rates on LCM therapy were 62.0% at 1 year, 43.7% at 2 years, and 29.1% at 3 and 4 years. Because there are a limited number of studies available on the retention rates of antiepileptic medications among patients with IDs, comparisons must also include general patient samples. Furthermore, studies investigating responder rates cannot be compared directly to studies on retention rates. 19, 20 In our sample, retention rates of 62% and 43.7% at 1 and 2 years, respectively, were almost the same as those reported by Novy et al. 5 (62% and 45%, respectively) and Flores et al. 21 (65% and 45%, respectively). However, our sample had lower retention rates at every single time point compared to the retention rates reported by Rosenow et al. 22 (62% vs. 74.5% at 1 year, 29.1% vs. 52.9% at 3 years, and 17.4% vs. 40.6% at 5 years). This discrepancy could be due to the different patient populations investigated.
With respect to AEDs other than LCM, the retention rate observed in the current study at 3 years (29.1%) seemed to Epilepsia ILAE be comparable to the 3-year retention rates of LTG (29%) and topiramate (TPM; 30%), as reported by Lhatoo et al. 23 However, it should be noted that their study was not conducted on patients with IDs. Comparing our data to another study conducted on patients with IDs, Carpay et al. reported higher retention rates at 3 years for LTG (70%), levetiracetam (LEV, 52%), and TPM (51%), and a comparable retention rate at 3 years for gabapentin (GBP, 33%). 24 The authors explained these relatively high retention rates by better tolerance, or a greater likelihood that cognitive and other adverse effects were overlooked due to communication barriers. To our knowledge, this is the first study to evaluate LCM retention rates among patients with epilepsy and IDs. Compared to previous studies conducted on other AEDs, retention rates in our sample were similar to those of patients without IDs.
A well-tolerated drug such as LCM will probably not be stopped early during the treatment course, whereas an AED with various side effects (e.g., TPM) will be discontinued earlier. 25 In the current study, noncensored patients stopped taking medications owing to low efficacy (69%); treatmentemergent AEs (11%) such as dizziness, fatigue, diplopia, and/or vomiting; or a combination of low efficacy and AEs (8%). Serious AEs, including atrioventricular blockade determined via electrocardiography or significant changes in laboratory parameters, were routinely screened for but none were reported. The low percentage of AEs in our sample, compared to the 42% reported by McGinnis et al. 9 or the 61% reported by Novy et al., 5 could be explained by differences in patient groups. More specifically, compared to patients with normal intellectual ability (such as those included in the two studies above), patients with IDs often are not able to report AEs. However, AEs are not the only factors that lead to discontinuation of LCM treatment. 9 Other reasons for LCM failure, as mentioned earlier, include lack of efficacy, an AED change made for treatment optimization, or unknown factors.
In further analyses, we investigated the impact of therapy-related factors on retention rates. LCM retention was influenced by the number of background AEDs; specifically, lower retention rates were observed in patients with higher numbers of background AEDs. LCM daily doses and treatment regimen (add-on compared to substitution) had no significant influence on retention rates. In a final analysis, we tested if the LCM retention rate was influenced by concomitant SCBs. In contrast to our expectation based on McGinnis et al., 9 our results indicated that there was no significant difference in retention rate in patients taking LCM and concomitant SCBs compared to patients taking LCM with no concomitant SCBs.
LCM has no known pharmacokinetic interaction with other AEDs, 1 and several trials have shown that LCM has no significant influence on the serum concentration of concomitant AEDs. 8 Concerning the influence of concomitant SCB use, several randomized, placebo-controlled, doubleblind, and postmarketing observational trials have been conducted. Of these trials, some, including the abovementioned studies by Flores et al. 21 and Novy et al., 5 did not notice an interaction between LCM and concomitant AED use. The primary focus of such trials was to evaluate the efficacy of LCM. 6, 7, 26 Other trials, which focused primarily on the tolerability of LCM, reported more neurotoxic AEs among patients taking LCM with concomitant SCBs. 8, 27 The design and methodology of our study is in concordance with the study by McGinnis et al., 9 which reported a significant difference between LCM retention rates in the presence and absence of concomitant SCB use. We can only speculate about the reasons for these contradictory results. Our data have shown that the number of background AEDs had a significant influence on retention rates. The division of our sample into a subgroup with SCBs and a subgroup without SCBs inevitably led to a higher total number of background AEDs in the group with SCBs. After controlling for the number of background AEDs, the influence of concomitant SCBs on retention rate was not significant. Table 1 of the report by McGinnis et al. 9 revealed a highly significant but uncontrolled difference in the number of concurrent AEDs at LCM start (p < 0.001) in children with concomitant SCBs compared children without concomitant SCBs.
We decided to use the Kaplan-Meier estimator to assess LCM effectiveness, as recommended by the International League Against Epilepsy (ILAE). 28 The Kaplan-Meier estimator is a combined measure for tolerability and efficacy, excluding the so called "honeymoon effect," which is associated with initial efficacy in drug-resistant patients. 29 In contrast to this approach, the well-established responder rate only describes drug efficacy. In the current study, we could have used responder rates to analyze our data; however, information about seizure frequency at baseline is difficult to obtain, and patients with IDs often do not keep seizure calendars. Moreover, not all seizures are seen by caregivers.
Retrospective chart reviews are a powerful methodology that can be used to gain systematic evaluations of clinical experiences in a real-world setting. However, there are considerable limitations associated with this methodology. For example, the retrospective nature of this study did not allow for countermeasures against dropouts, resulting in a relative high number of censored values. Furthermore, it was not possible to assess if dropouts were associated with treatment. The inclusion of a comparison group with a second AED would allow for more reliable conclusions about treatment effects. A second limitation resulted from the fact that some patients received LCM as an add-on medication, whereas others received LCM as a replacement for other AEDs. From a theoretical viewpoint, add-on therapies may result in better seizure outcome with lower tolerability due to higher total drug load. The opposite may be true for drug replacements. Even though our analysis did not reveal differences in retention rates between the add-on and replacement groups, future studies should use separate investigations with either add-on or replacement regimens. Finally, it should be noted that our sample represented a subset of patients with highly drug-resistant, medically intractable epilepsy, that is, multiple treatment regimens or high doses were required to attain at least some improvement in seizure control. This resulted in a prescribed mean daily dose of LCM that was higher than the maximum FDAapproved dose in the United States (411 mg vs. 400 mg). Thus our results may not be applicable to patients with more drug-responsive epilepsies.
In conclusion, the retention rate of LCM in this first monocentric, retrospective trial on 136 patients with IDs and drug-resistant epilepsy was comparable to the retention rate of other previously investigated AEDs. LCM retention rate was affected by the number of background AEDs but not by concomitant SCB use.
